Updated time: 2021-09-17 11:59:04
28A-1040918
US 10995067 B2、TW、PCT pending
Fabry disease (FD) is an inherited lysosomal metabolic disorder, and more than 300 missense mutations in the GLA gene have been identified. The activity of lysosomal α-galactosidase A (α-Gal A) is deficient to result into progressive accumulation of neutral glycosphingolipids in cells. Patients suffered from symptoms like chronic neuronopathic pain, gastrointestinal disturbances, angiokeratoma, cardiomyopathy, and premature myocardial infarctions. Inspired from naturally occurring polyhydroxylated pyrrolidines, we developed several synthetic molecules as chemical chaperones to rescue misfolding α-Gal A or (and) as stabilizers to improve the efficiency for enzyme replacement therapy (ERT).
Compared to the current known molecule, called DGJ, under investigation in clinical trial III, our some molecules shows better performance in potency or duration in several Fabry disease mutant cell lines.
The global treatment market for Fabry disease will expand in value from $683 million in 2014 to approximately $1.25 billion by 2024, driven primarily by rising physician awareness of the condition and consequently higher diagnosis rates, according to research and consulting firm GlobalData. Our discovery can be potentially applied into the treatment of Fabry disease:
- Development of new chemical chaperones to rescue misfolding proteins for the treatment of lysosomal storage diseases, especially for Fabry disease.
- Development of small molecules to improve the efficiency of enzyme replacement therapy (ERT) for the treatment of Fabry disease.
Wei-Chieh Cheng
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Polyhydroxylated pyrrolidine-based molecules as modulators for the treatment of Fabry disease